We are live on ! Find out more

LKFT

Lakefront Biotherapeutics American Depositary Shares

LKFT

Market cap $1.98B

30.19 USD

+0.60

2.03%

At close Updated Sep 22, 4:00 PM EDT

1 day

2.03%

5 days

8.09%

1 month

3.96%

3 months

4.32%

6 months

-5.36%

Year to date

-8.43%

1 year

-10.39%

5 years

-44.07%

10 years

-56.4%

About: Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.

Employees: 452

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 5%

Neutral 95%

Negative 0%

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig

Lakefront Biotherapeutics American Depositary Shares NASDAQ: LKFT said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines.

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig

Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Acquisition of Own Shares

Mechelen, Belgium; 15 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between September 07, 2026 and September 11, 2026 it has repurchased 125,517 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 07/09/2026 XAMS 22,861 24.44 558,763.99 24.20 24.56 07/09/2026 TQEX 1,166 24.43 28,486.20 24.26 24.56 07/09/2026 CEUX 157 24.47 3,842.47 24.44 24.56 08/09/2026 XAMS 23,629 24.23 572,611.01 23.98 24.52 08/09/2026 TQEX 1,705 24.33 41,475.66 24.28 24.38 08/09/2026 CEUX 2,044 24.23 49,533.68 24.00 24.40 08/09/2026 AQEU 492 24.26 11,937.89 24.06 24.36 09/09/2026 XAMS 22,015 23.91 526,444.69 23.64 24.12 09/09/2026 TQEX 527 23.90 12,596.56 23.82 24.02 09/09/2026 CEUX 2,355 23.95 56,410.73 23.84 24.10 09/09/2026 AQEU 914 24.01 21,941.21 23.86 24.08 10/09/2026 XAMS 20,285 23.64 479,622.60 23.24 23.96 10/09/2026 TQEX 827 23.56 19,487.01 23.30 23.92 10/09/2026 CEUX 1,917 23.28 44,631.21 23.26 23.34 10/09/2026 AQEU 984 23.78 23,395.19 23.68 23.92 11/09/2026 XAMS 20,038 23.45 469,987.28 23.20 23.66 11/09/2026 TQEX 492 23.62 11,619.47 23.52 23.64 11/09/2026 CEUX 2,640 23.38 61,727.95 23.20 23.60 11/09/2026 AQEU 469 23.52 11,030.32 23.44 23.62 Total 125,517 23.95 3,005,545.12 23.20 24.56 As of market close on September 11, 2026, Lakefront holds 1,418,855 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Acquisition of Own Shares

Lakefront Biotherapeutics: A Cash Discount With A More Credible Path To Value

Lakefront Biotherapeutics offers valuation support and clinical upside, leveraging a new development model post-Ouro acquisition and partnership with Gilead. LKFT's €2.24 billion liquidity and disciplined capital allocation provide runway through the first gamgertamig approval, with at least €1.6 billion projected post-approval. Gamgertamig's clinical promise targets difficult autoimmune diseases, but durable efficacy, safety, and competitive differentiation remain unproven and critical for future value.

Lakefront Biotherapeutics: A Cash Discount With A More Credible Path To Value

Acquisition of Own Shares

Mechelen, Belgium; 08 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 31, 2026 and September 04, 2026 it has repurchased 132,014 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 31/08/2026 XAMS 24,235 24.73 599,331.55 24.44 24.96 31/08/2026 AQEU 731 24.68 18,038.08 24.60 24.88 31/08/2026 CEUX 3,385 24.67 83,493.39 24.56 24.88 31/08/2026 TQEX 1,779 24.76 44,056.76 24.56 24.88 01/09/2026 XAMS 21,260 24.61 523,180.96 24.46 24.74 01/09/2026 AQEU 380 24.57 9,338.31 24.54 24.70 01/09/2026 CEUX 974 24.56 23,919.39 24.52 24.68 01/09/2026 TQEX 1 24.54 24.54 24.54 24.54 02/09/2026 XAMS 20,515 24.97 512,310.84 24.70 25.38 02/09/2026 AQEU 849 25.03 21,250.89 24.82 25.16 02/09/2026 CEUX 527 24.93 13,136.00 24.82 24.98 02/09/2026 TQEX 138 25.05 3,456.58 24.84 25.16 03/09/2026 XAMS 25,909 25.03 648,592.95 24.86 25.16 03/09/2026 AQEU 192 25.04 4,807.68 25.04 25.04 03/09/2026 CEUX 2,456 25.17 61,819.24 25.04 25.18 04/09/2026 XAMS 24,704 24.85 613,795.58 24.56 25.10 04/09/2026 AQEU 883 24.90 21,989.44 24.76 24.92 04/09/2026 CEUX 3,048 24.85 75,732.74 24.64 25.12 04/09/2026 TQEX 48 24.76 1,188.48 24.76 24.76 Total 132,014 24.84 3,279,463.42 24.44 25.38 As of market close on 04 September 2026, Lakefront holds 1,293,338 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Acquisition of Own Shares

Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Mechelen, Belgium; 8 September 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City at 5:35pm ET on Tuesday, September 15 th , 2026.

Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Acquisition of Own Shares

Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 24/08/2026 XAMS 21,820 24.56 535,857.74 24.36 24.64 24/08/2026 TQEX 450 24.55 11,045.43 24.54 24.60 24/08/2026 CEUX 328 24.58 8,062.37 24.54 24.64 24/08/2026 AQEU 1,333 24.61 32,811.40 24.58 24.66 25/08/2026 XAMS 21,058 25.29 532,464.16 24.94 25.52 25/08/2026 TQEX 698 25.25 17,623.66 25.00 25.36 25/08/2026 CEUX 600 25.28 15,165.48 25.24 25.34 25/08/2026 AQEU 313 25.29 7,914.33 25.26 25.34 26/08/2026 XAMS 22,968 25.45 584,632.07 25.08 25.64 26/08/2026 TQEX 599 25.45 15,241.91 25.30 25.64 26/08/2026 CEUX 1,703 25.47 43,377.62 25.24 25.66 26/08/2026 AQEU 539 25.50 13,744.72 25.32 25.60 27/08/2026 XAMS 21,382 25.27 540,406.53 25.06 25.36 27/08/2026 TQEX 904 25.27 22,843.72 25.20 25.32 27/08/2026 CEUX 2,342 25.24 59,114.89 25.12 25.36 27/08/2026 AQEU 440 25.23 11,100.50 25.12 25.34 28/08/2026 XAMS 25,694 25.29 649,927.16 25.00 25.50 28/08/2026 TQEX 1,110 25.40 28,194.11 25.36 25.46 28/08/2026 CEUX 3,363 25.38 85,342.18 25.08 25.46 28/08/2026 AQEU 152 25.26 3,840.17 25.14 25.46 Total 127,796 25.19 3,218,710.15 24.36 25.66 As of market close on 28 August 2026, Lakefront holds 1,161,324 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Acquisition of Own Shares

Acquisition of Own Shares

Mechelen, Belgium; 25 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 17, 2026 and August 21, 2026, it has repurchased 117,471 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 17/08/2026 XAMS 16,158 23.97 387,350.89 23.84 24.20 17/08/2026 CEUX 2,196 23.98 52,664.03 23.90 24.18 17/08/2026 TQEX 611 24.07 14,706.59 23.94 24.20 17/08/2026 AQEU 1,008 24.04 24,227.68 23.94 24.04 18/08/2026 XAMS 23,094 23.82 550,184.53 23.66 24.00 18/08/2026 CEUX 2,137 23.79 50,833.25 23.66 23.94 18/08/2026 TQEX 737 23.87 17,593.07 23.70 23.90 18/08/2026 AQEU 562 23.82 13,389.14 23.72 23.86 19/08/2026 XAMS 16,677 24.83 414,059.89 24.16 25.70 19/08/2026 CEUX 1,953 24.67 48,186.37 24.36 25.52 19/08/2026 TQEX 1,329 24.52 32,583.23 24.36 24.66 19/08/2026 AQEU 224 24.59 5,507.89 24.40 24.60 20/08/2026 XAMS 24,144 24.92 601,772.30 24.36 25.68 20/08/2026 CEUX 2,709 25.29 68,501.13 25.10 25.70 20/08/2026 TQEX 962 24.89 23,940.04 24.44 25.14 20/08/2026 AQEU 1,209 25.25 30,521.69 25.10 25.42 21/08/2026 XAMS 14,694 24.38 358,210.33 24.14 25.00 21/08/2026 CEUX 5,347 24.31 130,010.17 24.18 24.84 21/08/2026 TQEX 381 24.57 9,360.83 24.24 24.90 21/08/2026 AQEU 1,339 24.22 32,432.05 24.22 24.24 Total 117,471 24.40 2,866,035.10 23.66 25.70 As of market close on 21 August 2026, Lakefront holds 1,033,528 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Acquisition of Own Shares

U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus

Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).

U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus

Lakefront Receives Transparency Notification from Bank of America

Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.

Lakefront Receives Transparency Notification from Bank of America

See News Rankings

Price charts implemented using Lightweight Charts™